TheraRadar
Data updated: May 26, 2026

ICOSAPENT ETHYL

Cardiovascular Approved 2020-05-21

ICOSAPENT ETHYL is indicated for the treatment of Hypertriglyceridemia.

Source: FDA Label • Dr. Reddy's
13
Indications
--
Phase 3 Trials
6
Years on Market

Details

Status
Prescription
First Approved
2020-05-21
Routes
ORAL
Dosage Forms
CAPSULE

ICOSAPENT ETHYL Approval History

2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
22 FDA actions from 2020 to 2025
Aug 2025 ORIGINAL
Update
Dec 2024 ORIGINAL
Update
Nov 2024 ORIGINAL
Update

What ICOSAPENT ETHYL Treats

1 indications

ICOSAPENT ETHYL is approved for 1 conditions since its original approval in 2020. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Hypertriglyceridemia
Source: FDA Label

ICOSAPENT ETHYL Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to ICOSAPENT ETHYL

3 of 16

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

ATORVALIQ
ATORVASTATIN CALCIUM
1 shared
CMP DEV LLC
Shared indications:
CHOLESTYRAMINE
CHOLESTYRAMINE
1 shared
ALKEM LABS LTD
Shared indications:
CHOLESTYRAMINE LIGHT
CHOLESTYRAMINE
1 shared
PHARMOBEDIENT CNSLTG
Shared indications:
📋

Clinical Trial Registry

6 trials
Trial Sponsor ID Phase Status Title
NCT06466278 SALVAGE NL81780.018.22 Ph 2 active not recruiting IcoSApent ethyL to Slow Down Aortic VAlve Stenosis proGrEssion
NCT03428477 EMT2 MO16/053 Ph 3 active not recruiting EPA for Metastasis Trial 2
NCT04505098 MITIGATE 1597940 Ph 4 terminated A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults
NCT02422446 results posted 2013D003968 Ph 3 terminated Effects of Eicosapentaenoic Acid on Endothelial Function in Diabetic Subjects
NCT04177680 ENHANCE-IT results posted MAT-002 Ph 2 completed Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia
NCT04412018 Pro00043601 Ph 2 completed An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

ICOSAPENT ETHYL FDA Label Details

Indications & Usage

ICOSAPENT ETHYL is indicated for the treatment of Hypertriglyceridemia.

Looking for the branded version?

VASCEPA

Full clinical data, patents, trials, and competitive landscape for icosapent ethyl.

See VASCEPA

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.